Cell Thera licenses diabetes candidate to DiaKine
Under the terms of the agreement, Cell Therapeutics Inc (CTI) will receive license fees, together with milestone payments on the achievement of predetermined development goals, royalties on sales
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.